Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of miravirsen in treatment-naive chronic hepatitis C genotype 1
NL-OMON34513Phase 2Active, not recruiting
- Sponsor
- Santaris Pharma
- Start
- Sep 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing Miravirsen with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Sep 2010; status: active, not recruiting.
02
Drugs
miravirsen
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON34513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34513.